SCHEMBL24596290

SCHEMBL24596290

CCOC(=O)c1ncoc1-c1ccc(C(F)(F)F)cc1Nc1cccnc1C1CC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
BRD4 O60885 1/20 0.38
TRPV1 Q8NER1 1/20 0.37
CRHR1 P34998 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
TSHR P16473 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
P2RX7 Q99572 2/20 0.35
TAS2R14 Q9NYV8 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPK1 P28482 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29789898 1.00 MAPT (0.38) MAPTBRD4TRPV1CRHR1NPSR1
SCHEMBL24596211 0.88 MAPT (0.42) MAPTBRD4CRHR1NPSR1CACNA1B
SCHEMBL29789857 0.88 MAPT (0.42) MAPTBRD4CRHR1NPSR1CACNA1B
SCHEMBL29790055 0.85 BRD4 (0.37) MAPTBRD4TRPV1NPSR1CACNA1B
SCHEMBL24596365 0.85 BRD4 (0.37) MAPTBRD4TRPV1NPSR1CACNA1B
SCHEMBL29111652 0.76 TAS2R14 (0.43) TRPV1CRHR1CYP1A2CYP2C9TAS2R14
SCHEMBL24596321 0.75 BRD4 (0.43) MAPTBRD4TSHRMEN1KMT2A
SCHEMBL24596361 0.72 TGFBR1 (0.41) MAPTBRD4NPSR1CACNA1BAPBA1
SCHEMBL29790062 0.72 TGFBR1 (0.41) MAPTBRD4NPSR1CACNA1BAPBA1
SCHEMBL26631694 0.72 BRD4 (0.41) MAPTBRD4NPSR1CACNA1BAPBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A MAPT 466/4885BRD4 3607/4885TRPV1 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.